Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01243346 · ClinicalTrials.gov registry record · Phase 2
Study of Crenolanib for the Treatment of Patients With Advanced GIST With the D842-related Mutations and Deletions in the PDGFRA Gene
A Phase 2 study of D842-related Mutant GIST, sponsored by Arog Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 2
- Study locations
NCT01243346 is a Phase 2 study of D842-related Mutant GIST that has completed, run by Arog Pharmaceuticals. The registered enrollment target is 20 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT01243346, a Phase 2 study of D842-related Mutant GIST, has completed, sponsored by Arog Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 2
- Study locations
Study Summary
This Phase II study is designed to evaluate the antitumor efficacy and pharmacokinetics of crenolanib (CP-868,596) in patients with D842-related mutant metastatic GIST.
Conditions Studied
Interventions
- DRUG Crenolanib besylate (CP-868,596-26), Dose: 140mg BID
Study Locations (2)
Oregon
- Knight Cancer Institute, Oregon Health and Science University - Portland
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2011-04 |
| Est. Completion | 2014-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01243346
The ClinicalTrials.gov registry entry for NCT01243346 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arog Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with D842-related Mutant GIST appearing as the primary indexed condition, and to 1 intervention - of which Crenolanib besylate (CP-868,596-26), Dose: 140mg BID is the first listed.
NCT01243346 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Oregon, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01243346 about?
NCT01243346 is a clinical study titled "Study of Crenolanib for the Treatment of Patients With Advanced GIST With the D842-related Mutations and Deletions in the PDGFRA Gene". This Phase II study is designed to evaluate the antitumor efficacy and pharmacokinetics of crenolanib (CP-868,596) in patients with D842-related mutant metastatic GIST.
What is the current status of trial NCT01243346?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2011-04. Estimated completion is 2014-07.
What conditions does trial NCT01243346 study?
This clinical trial studies the following conditions: D842-related Mutant GIST.
What interventions are being tested in trial NCT01243346?
The interventions under investigation include: Crenolanib besylate (CP-868,596-26), Dose: 140mg BID (DRUG).
Who is sponsoring clinical trial NCT01243346?
This trial is sponsored by Arog Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01243346 being conducted?
This trial has 2 study locations across Oregon, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.